---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-097881"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:31:39.616366+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026

## Summary
- Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.
- Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).
- ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.
- Restructuring and program cuts expected to extend cash runway into Q4 2026.
- ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA.

## SEC filing metadata
- accession: 0000950170-25-097881
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/acet-20250722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-097881
- JSON: https://secwatch.observer/filing/0000950170-25-097881.json
- Plain text: https://secwatch.observer/filing/0000950170-25-097881.txt

## Key facts
- Restructurings & Charges
  Adicet Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 30% of the Company’s current employee base).
  - Type: restructuring
  - Charge: approximately $2.3 million
  - Headcount: approximately 30% of the Company’s current employee base
  source text: On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under Item 8.01 of this Current Report on Form 8-K. This workforce reduction will be substantially completed by the end of the third quarter of 2025. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $2.3 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the third quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.